At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 210 enrolled
Drug / intervention
Rifaximin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized,Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Rifaximin for the Prevention of Travellers' Diarrhea
In Brief
A Phase 3 clinical trial evaluating Rifaximin and Placebo for Diarrhea. Completed, enrolled 210 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if 600 mg of rifaximin, taken once a day for 14 days by healthy subjects, is safe and effective for the prevention of travellers' diarrhea compared to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiarrhea
CountriesMexico
Collaborators--
Timeline
Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2005
Primary CompletionSep 2005
Study CompletionApr 2007
First PostedAug 2008
TodayJul 2026
First PostedAug 27, 2008
Enrollment StartJun 1, 2005
Primary CompletionSep 1, 2005
Study CompletionApr 1, 2007
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 17.8 years ago
Interventions
Rifaximindrug
Placebodrug